Medscape Hematology-Oncology Headlines 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.DUO-E: PARP Inhibitor Combination Improves Survival DUO-E: PARP Inhibitor Combination Improves Survival
Dr Maurie Markman discusses results from the DUO-E trial.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Adding Apalutamide Boosts PSA Control in Prostate Cancer Adding Apalutamide Boosts PSA Control in Prostate Cancer
Adding apalutamide to androgen deprivation therapy (ADT) prolongs prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Will Germany Open the Gateway to Cannabis Medicine? Will Germany Open the Gateway to Cannabis Medicine?
Rescheduling cannabis won ' t solve the research glut.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2024 Category: Cancer & Oncology Tags: Psychiatry Source Type: news
Doc Sues State Over'Antiquated' Telehealth Rules Doc Sues State Over'Antiquated' Telehealth Rules
Antiquated laws requiring oncologists and other doctors offering telehealth to have medical licenses in multiple states unnecessarily restrict patient access, a New Jersey lawsuit claimed.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 2, 2024 Category: Cancer & Oncology Tags: Family Medicine/Primary Care Source Type: news
Team IDs Key Factors for Synthetic Control Arm in Mets CRC Team IDs Key Factors for Synthetic Control Arm in Mets CRC
Researchers identified a handful of prognostic factors to create a synthetic control arm, which can ultimately replace placebo control arms in future trials of salvage-line metastatic CRC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 2, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
WHO: Global Cancer Burden Rising Amid Striking Inequities WHO: Global Cancer Burden Rising Amid Striking Inequities
Globally, an estimated 20 million people developed cancer in 2022 -- a figure expected to increase 77% to 35 million by 2050, with poorer countries bearing the brunt, according to new data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Study Reveals Disparities in CRC Biomarker Testing Trends Study Reveals Disparities in CRC Biomarker Testing Trends
Testing trends are consistent with guideline recommendations and FDA approvals, but demographic disparities exist.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Top Causes of Early Noncancer Deaths in Advanced GU Cancers Top Causes of Early Noncancer Deaths in Advanced GU Cancers
Sepsis was the leading reason for early noncancer deaths in patients with metastatic bladder, kidney, or prostate cancer, a recent analysis found.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
' Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer
KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI
Men with metastatic castration-resistant prostate cancer had a slight but significant improvement in progression-free survival with a TKI plus immunotherapy vs hormonal therapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Patients State More Accurate Prognosis When in Poor Health Patients State More Accurate Prognosis When in Poor Health
Dr Maurie Markman discusses a paper focused on the controversial oncology topic of prognosis beliefs among patients with metastatic cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Unlikely Breakthrough of the Year: Chemo for Lung Cancer Unlikely Breakthrough of the Year: Chemo for Lung Cancer
Mark Kris makes the case that chemotherapy is the breakthrough of 2023 for lung cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Time for Universal Genetic Testing in Genitourinary Cancers Time for Universal Genetic Testing in Genitourinary Cancers
A new study supported universal germline genetic testing for genitourinary cancers to enhance risk assessment and guide tailored interventions.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Liver Status Improves Targeted Therapy Selection in Mets CRC Liver Status Improves Targeted Therapy Selection in Mets CRC
Adding liver metastases status to tumor sidedness may enhance first-line targeted treatment selection in certain patients with metastatic colorectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Healthier Lifestyle Linked to Lower Risk for Cancer Death Healthier Lifestyle Linked to Lower Risk for Cancer Death
A multicenter cohort study found that adhering to a healthy lifestyle including limiting alcohol intake and moderate physical activity could reduce cancer survivors ' risk for mortality.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
